The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

A recent study by Paula Luis and Claus Schneider, researchers in the Vanderbilt University School of Medicine Basic Sciences ...

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

The formulation comparison between a biosimilar and a branded biologic. The cost, availability, and supply chain benefits of ...

Fresenius said the U.S. Food and Drug Administration has approved a biologics license application for its operating company's bone-disease drugs. The approval concerns Fresenius Kabi's Conexxence and ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity ...